During cholestasis, accumulation of conjugated bile acids may occur in the liver and lead to hepatocellular damage. Inspired by our recent development of N-11 C-methyl-glycocholic acid-that is, 11 C-cholylsarcosine-a tracer for PET of the endogenous glycine conjugate of cholic acid, we report here a radiosynthesis of N-11 C-methyltaurine-conjugated bile acids and biodistribution studies in pigs by PET/CT. Methods: A radiosynthesis of N-11 C-methyl-taurine-conjugated bile acids was developed and used to prepare N-11 C-methyl-taurine conjugates derived from cholic, chenodeoxycholic, deoxycholic, ursodeoxycholic, and lithocholic acid. The lipophilicity of these new tracers was determined by reversed-phase thin-layer chromatography. The effect of lipophilicity and structure on the biodistribution was investigated in pigs by PET/CT using the tracers derived from cholic acid (3α-OH, 7α-OH, 12α-OH), ursodeoxycholic acid (3α-OH, 7β-OH), and lithocholic acid (3α-OH). Results: The radiosyntheses of the N-11 C-methyl-taurine-conjugated bile acids proceeded with radiochemical yields of 61% (decay-corrected) or greater and radiochemical purities greater than 99%. PET/CT in pigs revealed that the tracers were rapidly taken up by the liver and secreted into bile. There was no detectable radioactivity in urine. Significant reflux of N-11 C-methyltaurolithocholic acid into the stomach was observed. Conclusion: We have successfully developed a radiosynthesis of N-11 C-methyl-taurineconjugated bile acids. These tracers behave in a manner similar to endogenous taurine-conjugated bile acids in vivo and are thus promising for functional PET of patients with cholestatic diseases.
Bi le acids, the end products of cholesterol metabolism, are formed in the liver and secreted into bile where their total concentration exceeds that of any other metabolite. They play an essential role in the biliary excretory function of the liver, in intestinal dietary lipid absorption, and in metabolic signaling (1) (2) (3) (4) (5) . Human bile contains mainly the primary bile acids, cholic acid (CA) and chenodeoxycholic acid (CDCA), formed from cholesterol in the hepatocytes, but also secondary bile acids such as deoxycholic acid (DCA), ursodeoxycholic acid (UDCA), and lithocholic acid (LCA) formed by transformation of the primary bile acids by colonic bacteria. Before secretion from the hepatocytes, all bile acids are conjugated with glycine or taurine at their terminal side chain carboxylic acid group. Although affected by diet and certain cholestatic liver diseases, glycine conjugates dominate in humans (6, 7) , whereas taurine conjugates dominate in many other species (8, 9) . Conjugation increases the polarity and hence decreases the lipophilicity (lipophilicity 5 hydrophobicity -polarity) of the bile acids, particularly in the case of conjugation with taurine because of its intrinsically stronger sulfonic acid group compared with the carboxylic acid group of glycine. The lipophilicity of conjugated bile acids is also affected by differences in hydrophobicity dictated by the number and configuration (a or b) of hydroxyl groups (-OH) on the steroidal backbone.
Virtually all conjugated bile acids are recovered at the terminal ileum and returned to the liver with portal circulation. At the sinusoidal membrane of hepatocytes, they are taken up mainly by the Na 1 -taurocholate cotransporting polypeptide (NTCP), whereas their biliary secretion is governed by the bile salt export pump (BSEP) located at the canalicular membrane of hepatocytes (10) . BSEP constitutes the rate-limiting step of the overall bile acid transport across hepatocytes and has a high affinity for taurineand glycine-conjugated bile acids, with the highest affinity for the former (11, 12) . Impairment of BSEP is associated with inherited cholestatic liver diseases including progressive familial intrahepatic cholestasis type 2 and benign recurrent intrahepatic cholestasis type 2 and in acquired forms of cholestasis such as intrahepatic cholestasis of pregnancy and drug-induced liver injury (13) .
To study the hepatic transport of conjugated bile acids in vivo, we recently developed N-11 C-methyl-glycocholic acid ( 11 C-MGCA)-that is, 11 C-cholylsarcosine ( 11 C-CSar) (14, 15) . 11 C-MGCA is a synthetic analog of the endogenous glycine conjugate of CA, that is, glycocholic acid (GCA). Despite the additional methyl-group, 11 C-MGCA behaves in a manner similar to GCA and has proven to be a suitable PET tracer for cholestatic conditions (16) (17) (18) . The only significant (and beneficial) difference caused by the N-methyl-group, is that 11 C-MGCA, unlike endogenous bile acid conjugates, is stable toward deconjugation and dehydroxylation by colonic bacteria. Here we report a radiosynthesis of N-11 C-methyl-taurineconjugated bile acids and present 5 novel N-11 C-methyl-taurine conjugates derived from primary and secondary bile acids of different lipophilicity ( Fig. 1) (15) . We also report results of PET/CT studies of biodistribution in pigs and dosimetry calculations for the structurally different tracers 11 C-MTCA (N-11 C-methyltaurocholic acid), 11 C-MTUDCA (N-11 C-methyl-tauroursodeoxycholic acid), and 11 C-MTLCA (N-11 C-methyl-taurolithocholic acid), with 11 C-MTCA (3a-OH, 7a-OH, 12a-OH) and 11 C-MTUDCA (3a-OH, 7b-OH) being the least lipophilic and 11 C-MTLCA (3a-OH) being the most lipophilic of the developed tracers.
MATERIALS AND METHODS

Chemicals
CA, CDCA, DCA, UDCA, LCA, GCA sodium salt hydrate, TCA sodium salt hydrate, taurine, 1,2,2,6,6-pentamethylpiperidine (PMP), diethyl phosphoryl cyanide (DEPC), and anhydrous dimethylsulfoxide (DMSO) were obtained from Sigma-Aldrich and used as received. Nonradioactive MTCA, N-methyl-taurochenodeoxycholic acid (MTCDCA), N-methyl-taurodeoxycholic acid (MTDCA), MTUDCA, and MTLCA were prepared as described in the supplemental data (available at http:// jnm.snmjournals.org). Nonradioactive MGCA, that is, cholylsarcosine (CSar), was prepared as described previously (14) . The sodium and potassium salts of taurine were prepared by treating taurine with 1 equivalent of aqueous NaOH or KOH, respectively, followed by evaporation of the solvent and oven-drying. European Pharmacopoeia-grade acetonitrile and analytic-grade methanol, NaOH (solid), KOH (solid), and glacial acetic acid were obtained from VWR International Ltd. and used as received. Water (sterile), saline (sterile), ethanol (sterile), and 70 mM aqueous NaH 2 PO 4 (sterile, pH 4.5) were obtained from the pharmacy at Aarhus University Hospital. Sep-Pak C8 Plus Short Cartridges (400 mg sorbent/cartridge, 37-55 mm particle size) were obtained from Waters and preconditioned before use with 10 mL of sterile ethanol followed by 10 mL of sterile water.
The N-11 C-methyl-taurine-conjugated bile acids were prepared by a 2-step 1-pot radiosynthesis ( Fig. 2) : the radionuclide was produced by the 14 N(p,a) 11 C nuclear reaction using an IBA Cyclone 18/18 cyclotron. The applied target gas mixture (N 2 with 0.5% O 2 ) was bombarded at 30 mA for 15-30 min to yield 11 C-CO 2 . The 11 C-CO 2 was delivered to the synthesis system (Tracerlab FXcPro; GE Healthcare) and converted to 11 C-CH 4 for further gas phase reaction with molecular iodine to 11 C-CH 3 I. Fifteen minutes after the end of bombardment, the 11 C-CH 3 I was released from the Porapak N at 190°C and transferred to the reactor of the synthesis system preloaded with a solution of the oven-dried precursor taurine sodium salt (1 mg) dissolved in anhydrous DMSO (300 mL). The 11 C-CH 3 I was slowly bubbled through the precursor solution (helium flow, 15 mL/min) until maximum activity was trapped in the reactor. The 11 C-methylation of taurine was achieved by heating at 80°C for 3 min to give N-11 C-methyltaurine. After the reactor was cooled to 65°C, freshly prepared solutions of the bile acid (12 mg) and PMP (5 mL) in anhydrous DMSO (200 mL), and DEPC (5 mL) in anhydrous DMSO (100 mL) were added successively through dry tubing directly into the reactor solution of N-11 C-methyl-taurine. The coupling reaction was allowed to proceed for 5 min at 65°C before quenching the reaction with sterile 20% aqueous ethanol (0.7 mL). The crude reaction mixture was purified by preparative reversed-phase high-pressure liquid chromatography using a Synergi Hydro-RP column (4 mm, 21.2 · 100 mm; Phenomenex) and with 30%-40% acetonitrile in sterile 70 mM aqueous NaH 2 PO 4 buffer (pH 4.5) as the mobile phase (flow, 15 mL/min; l 5 220 nm). The fraction containing the N-11 C-methyl-taurine-conjugated bile acid (retention time, 5-10 min) was collected and diluted with 50 mL of sterile water and then extracted from this solution using a preconditioned C8-catridge. The purified product was eluted from the cartridge using sterile ethanol (1.0 mL) and finally formulated with sterile saline (9.0 mL). Total synthesis time, including 11 C-CH 3 I production and tracer purification, was 40 min from the end of bombardment.
The radiochemical conversion of the reactions (determined from samples of the crude reaction mixtures) and the identity and radiochemical purity of the isolated N-11 C-methyl-taurine bile acid conjugates were determined by liquid chromatography (LC) mass spectroscopy (MS) (LC: Dionex system; MS: Bruker Daltonics HCT Plus ion trap mass spectrometer running in negative ionization mode; the supplemental data provide information for further MS settings) connected in series to a Gabistar radiodetector (Nuclear Interface). The chromatographic column for analysis was a Synergi 4 mm MAX-RP 80A (2.0 · 100 mm; Phenomenex) with 30%-46% acetonitrile in aqueous ammonium acetate (1 mM; pH 3.0, adjusted using glacial acetic acid) as isocratic eluent with a flow of 0.9 mL/min (details are provided in the supplemental data). The chromatographic radio-and MS signals were analyzed using Dionex Chromeleon software (version 6.80) and Bruker Daltonics esquireControl (version 5.3), respectively. The identities of the 11 C-labeled bile acid conjugates were confirmed by comparison of retention time and mass spectrum with that of the corresponding 12 C bile acid conjugates.
Determination of Lipophilicity by Reversed-Phase Thin-Layer Chromatography
The lipophilicity of MGCA (CSar), MTCA, MTCDCA, MTDCA, MTUDCA, MTLCA as well as GCA, TCA, and CA was determined by reversed-phase thin-layer chromatography (stationary phase, C18; mobile phase, methanol/aqueous ammonium acetate [pH 7.40]) and reported as values of R Mw and S, where R Mw reflects the lipophilicity of the compoundthat is, the higher the value of R Mw , the more lipophilic-and S the degree of responsiveness to changes in the mobile phase composition (details are provided in the supplemental data).
PET/CT Biodistribution and Dosimetry in Pigs
Biodistribution and dosimetry was determined in 2 pigs (3-mo-old female Danish Landrace and Yorkshire cross-breed) by PET/CT for 11 C-MTCA, 11 C-MTUDCA, and 11 C-MTLCA after an 18-h fasting with free access to water. The pigs were premedicated with midazolam and s-ketamine; anesthetized with a mixture of midazolam, s-ketamine, and propofol; and mechanically ventilated as previously described (19) . A catheter (Cordis) was inserted into the femoral vein for administration of the tracers. Blood pressure; heart rate; body temperature; and arterial blood pO 2 , pCO 2 , pH, and glucose were monitored continuously and disturbances corrected for by appropriate procedures (19) . After completion of the experiment, the animals were euthanized with an overdose of pentobarbital (100 mg/kg). The studies were performed according to the Danish Animal Experimentation Act and the European convention for the protection of vertebrate animals used for experimental and other purposes (European Treaty Series no. 123).
The PET/CT studies were performed with the pigs placed supine in a Siemens Biograph 64 Truepoint PET/CT camera with a 21.6-cm axial PET field of view. A CT scan (250 effective mAs with CARE Dose4D [Siemens], 120 kV, pitch of 1.0, and slice thickness of 2.0 mm) was obtained for definition of anatomic structures and attenuation correction of the PET recordings. Pig 1 (body weight, 41 kg) was administered 11 C-MTCA (511 MBq), 11 C-MTUDCA (508 MBq), and then 11 C-MTLCA (486 MBq), whereas pig 2 (body weight, 36 kg) was administered 11 C-MTLCA (536 MBq), 11 C-MTCA (571 MBq), and then 11 C-MTUDCA (553 MBq). The tracers were administered as intravenous bolus injections, and at least 7 physical half-lives of the 11 C radioisotope (half-life, 20.4 min) were allowed to pass between each administration. After administration of the tracer, 6 whole-body PET scans, each with 6 bed positions, were obtained with 3 min between scans and with a progressive increase in scan duration per bed position of 1, 1, 1.5, 2, 3, and 5 min. Thus, each whole-body scan was started 1, 10, 19, 30, 45, and 68 min after tracer injection. Whole-body images were reconstructed using 3-dimensional ordered-subset expectation maximization with 6 iterations and 21 subsets and a 2-mm Gauss filter. All tissues were visually inspected, and organs with accumulation of tracer above that of surrounding tissue were defined as source organs. These organs were liver tissue, gallbladder contents, stomach contents, and small intestine contents. No measurable radioactivity was observed in other organs including kidneys and urinary bladder; urine samples verified that no tracer was excreted in urine. Volumes of interest were manually drawn in each source organ to encompass all radioactivity of the respective organs. Intrahepatic 11 C-MTCDCA 75% ± 4% 26% ± 3% 68% ± 4% 4.7-6.4 GBq .99%
11 C-MTDCA 77% ± 2% 25% ± 4% 61% ± 8% 2.2-6.2 GBq .99%
11 C-MTUDCA 77% ± 4% 25% ± 3% 66% ± 6% 2.5-6.0 GBq .99%
11 C-MTLCA 77% ± 6% 22% ± 1% 65% ± 7% 1.9-4.5 GBq .99%
*Radiochemical conversion (mean ± SD, n 5 3-5) was estimated from LC-radio-MS analysis of crude reaction mixture. † Radiochemical yield (mean ± SD, n 5 3-5) is based on amount of isolated radioactivity after purification and relative to amount of 11 C-methyl iodide initially trapped in reactor. ‡ Isolated radioactivity amount of purified product (n 5 3-5). ¶ Radiochemical purity was determined by LC-radio-MS analysis of final product formulation (n 5 3-5).
bile ducts were included in the volume of interest of the liver, whereas the choledochus was included in the volume of interest of the small intestines.
For each source organ, the time course of the non-decay-corrected total radioactivity was extracted and recalculated into time courses of percentage injected dose using injected dose, organ masses, organ densities, and total weight for the reference adult man (20) . Residence times were computed using the trapezoidal integration method to calculate the area under the curves assuming only physical decay after the last scan, without further biologic clearance. The remainder fraction was calculated by subtracting the individual source organ residence times from the totalbody residence time (without voiding), which for 11 C is 0.49 h. Residence times for source organs and remainder were used in OLINDA/ EXM 1.0 (21) to compute organ doses using the male reference phantom and to obtain an effective dose estimate according to International Commission on Radiological Protection publication 60 (22) .
RESULTS
Radiochemistry
The N-11 C-methyl-taurine-conjugated bile acids 11 C-MTCA, 11 C-MTCDCA, 11 C-MTDCA, 11 C-MTUDCA, and 11 C-MTLCA (1.9-6.4 GBq; Table 1 ) were prepared with high radiochemical conversion (75%-78%), good radiochemical yield (22%-30%; not decay-corrected), excellent radiochemical purity (.99%), and specific activities in the range of 30-55 GBq/mmol. No protection of the sulfonic acid group of taurine or the hydroxyl groups of the parent bile acids was needed. During optimization of the radiosynthesis, we found that moisture significantly affected the radiochemical conversion of the reaction. The results presented in Table 1 are all based on reactions performed using an oven-dried taurine precursor, dry DMSO, fresh PMP, and fresh DEPC (less than 3 mo old) as well as a rigorously dried synthesis system. If these precautions were not taken, the radiochemical conversion generally dropped to approximately 50%.
Lipophilicity
R Mw values for nonradioactive MGCA (CSar), MTCA, MTCDCA, MTDCA, MTUDCA, and MTLCA are reported in Figure 3 . For comparison, the lipophilicity of GCA, TCA, and unconjugated CA was also determined. Values of S are reported in Figure 3 in parentheses. As expected, conjugation significantly decreased the lipophilicity of the bile acids. In addition, taurine conjugates were less lipophilic than glycine conjugates, that is, R Mw (CA) . R Mw (GCA) . R Mw (TCA), whereas a methyl group on the amide nitrogen of a conjugated bile acid slightly increased the lipophilicity, that is, R Mw (MGCA) . R Mw (GCA) and R Mw (MTCA) . R Mw (TCA), although not compensating for the decreased lipophilicity due to conjugation. The results in Figure 3 also show that the number and configuration of hydroxyl groups on the parent bile acid significantly influence the lipophilicity and give rise to the following ranking of the N-methyl-taurine-conjugated bile acids:
, which corresponds to that of endogenous taurine-conjugated bile acids (23) .
Biodistribution and Dosimetry in Pigs
PET/CT revealed a similar biodistribution pattern for 11 C-MTCA, 11 C-MTUDCA, and 11 C-MTLCA in the pigs. Figure 4 shows wholebody PET/CT images recorded 1, 10, 19, 30, 45, and 68 min (start of scan) after administration of 11 C-MTCA in pig 2. The images show that the tracer is rapidly taken up by the liver and secreted into bile.
After secretion into the small intestines, the tracer returns to the liver as a result of enterohepatic recirculation (Fig. 4, 68-98 min) . Further whole-body PET/CT images of the tracers in the 2 pigs and the time-activitycurves used for dosimetry calculations are provided in the supplemental data. Dosimetry data for 11 C-MTCA, 11 C-MTUDCA, and 11 C-MTLCA are presented in Table 2 together with data for 11 C-MGCA ( 11 C-CSar) previously published (14) . Only organs receiving the highest doses are presented in this table. The supplemental data provide a full list of organs. The small intestine and stomach wall were identified as critical organs. The varying distribution of the tracers in the small intestines and gallbladder is considered to reflect the normal physiologic distribution of bile acids. The calculated effective doses were 4.4 6 0.2, 5.5 6 0.2, and 8.3 6 0.9 mSv/MBq for 11 C-MTUDCA, 11 C-MTCA, and 11 C-MTLCA, respectively. The effective dose for 11 C-MGCA ( 11 C-CSar), approximately 4.4 mSv/MBq, was similar to that of 11 C-MTUDCA and 11 C-MTCA. The large difference between 11 C-MTLCA and the other tracers was due to a significantly higher dose received by the stomach wall when the pigs were administered 11 C-MTLCA.
DISCUSSION
As part of an ongoing program on in vivo quantification of hepatic transport of conjugated bile acids by PET (14), we here report the development of a radiosynthesis of N-11 C-methyl-taurine-conjugated bile acids (15) and present 5 11 C-labeled conjugates derived from common primary and secondary bile acids.
In humans, only about 5% of the bile pool is from de novo synthesis in the liver; the remaining part recirculates in the enterohepatic circulation. Both primary and secondary bile acids in the intestine (mostly present as conjugates of glycine or taurine) are taken up from the terminal ileum, brought to the liver via portal circulation, and presented to hepatocytes in the sinusoids. Here, conjugated bile acids are taken up mainly by the NTCP and resecreted into the bile canaliculi mainly by the BSEP (10, 24) . Although the hepatic uptake of bile acids returning from the intestine is highly efficient, a small portion of bile acids escape uptake and enter the systemic circulation. Bile acids spilled into the system circulation, however, are again brought to the liver by the hepatic artery, which mixes with the portal vein before reaching the sinusoids so the residence time of any bile acid in systemic circulation is only a few minutes (2) .
Preliminary results in pigs indicate that Ntcp and Bsep are indeed the main transporters of 11 C-MGCA, a tracer analog of endogenous glycocholic acid (14) . We expect this to be the case for the 11 C-methyltaurine-conjugated tracers presented here as well. In general, NTCP/ Ntcp and BSEP/Bsep in humans, mice, and rats have been shown to have higher affinity for conjugates of dihydroxy bile acids, that is, conjugates of CDCA and DCA, than conjugates of the trihydroxy bile acid CA, and with higher affinity for taurine than glycine conjugates (10) (11) (12) 25) . In particular, the affinity of BSEP for conjugated bile acids can be ranked as TCDCA . TCA . TUDCA . GCA (11) . Hence, it is likely that the affinity of this essential bile acid transporter will also be higher for 11 C-MTCDCA than for 11 C-MGCA.
We expect that the tracers presented here do not metabolize on the time scale of a 11 C PET study. It has been shown that nonradioactive MTUDCA (26) and MGCA (27, 28) are highly resistant to metabolism in rats, hamsters, rabbits, and humans. Also, no metabolites have been observed for 11 C-MGCA in pigs (14) . It is the additional N-methyl-group that makes these compounds highly resistant toward deconjugation and dehydroxylation by colonic bacteria. On the basis of the knowledge of the metabolism of endogenous TLCA, however, it is possible that 11 C-MTLCA, the most lipophilic of the developed tracers, will be metabolized in humans by esterification with sulfate at its 3-hydroxy group and in rodents also by hydroxylation at carbon 6 or 7 (29) .
The biodistribution studies of the 3 N-11 C-methyl-taurineconjugated mono-, di-, and trihydroxy bile acids, 11 C-MTLCA, 11 C-MTUDCA, and 11 C-MTCA, revealed that these tracers, like their endogenous taurine analogs, have the highest concentrations in bile ducts, gallbladder, and small intestines compared with other tissues. The effective doses for the 3 tracers were similar to other 11 C-labeled tracers including 11 C-MGCA (14) . The present doses of approximately 0.5 GBq were used in the pigs to obtain good counting statistics. However, because of the high specificity and the rapid distribution of the tracers, 100 MBq, which is a typical dose for 11 C-MGCA in a 70-kg human, will be sufficient to obtain a similar data quality in human studies and lead to effective doses in the range 0.4-0.8 mSv corresponding to approximately 10% of the natural background radiation in Denmark. Interestingly, for 11 C-MTLCA we observed a significant amount of radioactivity in the stomach. Thus, the most affected single organ in this case was the stomach wall (53.2 mGy/MBq), which is equivalent to 5.3 mSv for an injection of 100 MBq and below common regulatory dose limits. In healthy persons, little gastroduodenal reflux is observed. However, in patients with disordered gastroduodenal motility or pyloric sphincter dysfunction, reflux may occur (2) . This should be kept in mind particularly when administering 11 C-MTLCA to such patients, because they would receive a higher radiation dose than patients without these disorders. Also, changes in the biodistribution and effective dose should be anticipated in cholestatic patients for all presented tracers.
CONCLUSION
A 2-step 1-pot radiosynthesis of N-11 C-methyl-taurine-conjugated bile acids has successfully been developed and used to prepare the N-11 C-methyl-taurine conjugates of CA, CDCA, DCA, UDCA, and LCA with good radiochemical yield and excellent radiochemical purity. It is known that N-methyl-taurine (and N-methyl-glycine)-conjugated bile acids, unlike their corresponding endogenous taurine (and glycine) conjugates, are resistant toward biodegradation. The additional N-methyl-group makes the novel tracer analogs only slightly more lipophilic than their corresponding endogenous conjugates; their overall ranking according to lipophilicity still corresponds to that of the endogenous conjugates. In addition, biodistribution studies of the 3 structurally different tracers derived from cholic (3a-OH, 7a-OH, 12a-OH), ursodeoxycholic (3a-OH, 7b-OH), and lithocholic (3a-OH) acid have shown that the tracers behave in a manner similar to endogenous taurine-conjugated bile acids in vivo, with no detectable elimination in urine. Effective radiation doses have been determined to be in the range 4.4-8.3 mSv/MBq, similar to other 11 C-labeled tracers. We believe that these new N-11 C-methyl-taurine-conjugated bile acids will prove useful for preclinical tests in animals with a naturally high level of taurineconjugated bile acids and for detailed studies of patients with intrahepatic cholestatic disorders.
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